menu
    • menu

    Company profile for Volastra Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Volastra Therapeutics, Inc., is developing novel therapies to treat cancer. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of solid tumors. Following initial evidence that a patient’s CIN status is prognostic and that CIN alters cellular and immune response mechanisms and leads...
    Volastra Therapeutics, Inc., is developing novel therapies to treat cancer. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of solid tumors. Following initial evidence that a patient’s CIN status is prognostic and that CIN alters cellular and immune response mechanisms and leads to worse overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates disease to develop novel therapeutics.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Volastra TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1361 Amsterdam Ave Suite 520 New York, NY 10027
    Telephone
    Telephone
    (646) 344-1248
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.volastratx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/volastra-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Volastra Therapeutics Appoints David P. Southwell as CEO
    Volastra Therapeutics Appoints David P. Southwell as CEO

    27 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250527677059/en/Volastra-Therapeutics-Announces-Appointment-of-David-P.-Southwell-as-Chief-Executive-Officer

    BUSINESSWIRE
    27 May 2025
    Share Share
    Volastra to Present Initial Data on KIF18A Inhibitor at 2025 ASCO
    Volastra to Present Initial Data on KIF18A Inhibitor at 2025 ASCO

    22 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250522033030/en/Volastra-Announces-Initial-Data-from-First-in-Human-Phase-III-Trial-of-Novel-KIF18A-Inhibitor-VLS-1488-to-be-Presented-at-2025-ASCO-Annual-Meeting

    BUSINESSWIRE
    22 May 2025
    Share Share
    Volastra taps CSO as it looks to expand research horizons
    Volastra taps CSO as it looks to expand research horizons

    16 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/chromosomal-instability-biotech-volastra-therapeutics-steadies-itself-growth-new-chief

    FIERCE BIOTECH
    16 Oct 2024
    Share Share
    Volastra Appoints Samuel Bakhoum As Chief Scientific Officer
    Volastra Appoints Samuel Bakhoum As Chief Scientific Officer

    16 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241016855401/en

    BUSINESSWIRE
    16 Oct 2024
    Share Share
    Volastra's Ovarian Cancer Drug Gets FDA Fast Track Status
    Volastra's Ovarian Cancer Drug Gets FDA Fast Track Status

    02 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241002653121/en

    BUSINESSWIRE
    02 Oct 2024
    Share Share
    Volastra Doses First SovilnesibPhase 1b Patient
    Volastra Doses First SovilnesibPhase 1b Patient

    16 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240416246457/en

    BUSINESSWIRE
    16 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search